This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
by Zacks Equity Research
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCYNegative Net Change NVSNegative Net Change LLYNegative Net Change NBIXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio
by Kinjel Shah
Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
IVZPositive Net Change GMPositive Net Change NXPositive Net Change HPEPositive Net Change HRMYNegative Net Change
auto-tires-trucks biotechs computers medical pharmaceuticals
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
by Zacks Equity Research
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
ALKSNegative Net Change LQDANegative Net Change KNSANegative Net Change HRMYNegative Net Change
biotechs earnings
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
by Ahan Chakraborty
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
LLYNegative Net Change AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
by Deepanwita Sarkar Saha
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
REGNPositive Net Change BIIBNegative Net Change BMYPositive Net Change ABBVNegative Net Change VKTXNegative Net Change
biotechs medical
Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?
by Zacks Equity Research
Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.
REGNPositive Net Change SNYPositive Net Change BMYPositive Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Zacks Equity Research
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
by Zacks Equity Research
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
AZNNegative Net Change SNYPositive Net Change MRKPositive Net Change AMGNNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Sundeep Ganoria
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
BIIBNegative Net Change INSMNegative Net Change AGIONegative Net Change ACADNegative Net Change HRMYNegative Net Change
biotechs earnings
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
by Kanishka Das
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
IMCRNegative Net Change BMYPositive Net Change MRKPositive Net Change
biotechs